Compositions for use in the prevention or treatment of URT infections in infants or young children at risk
View Patent ↗The present invention relates to a composition comprising at least one fucosylated oligosaccharide, for use in preventing and/or treating URT infections in an infant or young child fulfilling at least one of the following criteria: i) the infant or young child is born from a non-secretor mother and/or is fed with a mother's milk deficient in at least one fucosylated oligosaccharide(s) ii) the infant or young child has at least one sibling iii) the infant or young child was born by C-section.
1. A method for treating an upper respiratory tract (URT) infection in an infant or young child in need thereof, the upper respiratory tract infection selected from the group consisting of epiglottitis, laryngitis, tonsillitis, laryngotracheitis, tracheitis, and combinations thereof, the method comprising administering a composition comprising 0.5 to 10 g/L of at least one fucosylated oligosaccharide to an infant or young child in need thereof wherein said infant or young child has at least one sibling and is fed with a mother's milk deficient in at least one fucosylated oligosaccharide, the composition is administered in a daily dose that provides 0.1 to 4 g of the at least one fucosylated oligosaccharide to the infant or the young child per day.
2. The method according to claim 1 wherein the at least one fucosylated oligosaccharide is selected from the group consisting of 2′-fucosyllactose, 3′fucosyllactose, difucosyllactose, lacto-N-fucopentaose I, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-fucohexaose, lacto-N-difucohexaose I, fucosyllacto-N-hexaose, fucosyllacto-N-neohexaose I, fucosyllacto-N-neohexaose II, difucosyllacto-N-hexaose I, difucosyllacto-N-neohexaose I, difucosyllacto-N-neohexaose II, fucosyl-para-Lacto-N-hexaose, and combinations thereof.
3. The method according to claim 1 wherein the at least one fucosylated oligosaccharide comprises a 2′ fucosyl-epitope.
4. The method according to claim 1 wherein the at least one fucosylated oligosaccharide is 2′ fucosyllactose.
5. The method according to claim 1 wherein the composition administered to the infant or young child comprises 5 to 10 g/L of the at least one fucosylated oligosaccharide.
6. The method according to claim 1 comprising at least another human milk oligosaccharide and/or precursor thereof.
7. The method according to claim 6 wherein the at least one human milk oligosaccharide and/or precursor thereof is selected from the group consisting of N-acetylated oligosaccharide, sialylated oligosaccharide, sialic acid, fucose and combinations thereof.
8. The method according to claim 7 , wherein the N-acetylated oligosaccharide is selected from the group consisting of lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT) and combinations thereof.
9. The method according to claim 7 , wherein the sialylated oligosaccharide is selected from the group consisting of 3′ sialyllactose (3-SL), 6′ sialyllactose (6-SL), and combinations thereof.
10. The method according to claim 1 comprising at least another human milk oligosaccharide and/or precursor thereof selected from the group consisting of lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3′ sialyllactose (3-SL), 6′ sialyllactose (6-SL), sialic acid and combinations thereof.
11. The method according to claim 1 , wherein the composition further comprising at least one probiotic in an amount of from 10 3 to 10 12 cfu/g of said composition (dry weight).
12. The method according to claim 1 , wherein the composition is selected from the group consisting of a nutritional composition, a preparation and a food product.
13. The method according to claim 1 , wherein the composition is selected from the group consisting of an infant formula, a starter infant formula, a follow-on infant formula, a baby food, an infant cereal composition, a fortifier and a supplement.
14. The method according to claim 1 , wherein the infant or young child is preterm.
15. The method according to claim 1 , wherein the infant or young child is a secretor.
16. The method according to claim 1 , wherein the composition is administered in a daily dose that provides 0.1 to 2 g of the at least one fucosylated oligosaccharide to the infant or the young child per day.
17. The method according to claim 1 , wherein the composition comprises lacto-N-tetraose (LNT) and lacto-N-neotetraose (LNnT) in a ratio LNT:LNnT between 5:1 and 1:2.